The suspension of the ATM program signals that Nuvectis is not currently pursuing at-the-market equity issuance, which reduces near-term dilution risk. Monitor for any future prospectus filing if the company resumes sales. No immediate catalyst for stock movement.
Price Chart
Executive Summary
Nuvectis Pharma filed an 8-K announcing it is reducing the available amount under its Sales Agreement with Leerink Partners to $5 million and suspending the associated prospectus. The company will not make any sales under the agreement unless a new prospectus or registration statement is filed. This is an administrative update with no material financial impact.
Key Facts
- Company lowered the amount available for sales under the Sales Agreement Prospectus to $5 million.
- Company is suspending the Sales Agreement Prospectus and will not make any sales unless a new prospectus is filed.
- The Sales Agreement with Leerink Partners remains in full force and effect.
- No sales of common stock are being made under the agreement at this time.
Financial Impact
No financial impact — the action is a voluntary reduction and suspension of an ATM facility, with no sales executed.
Risk Factors
- Company could resume sales under a new prospectus, reintroducing dilution risk.
- No change to underlying business fundamentals or pipeline progress.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-078823 |
| Document: 0001104659-26-078823-index-headers.html | 0001104659-26-078823 |
| Document: 0001104659-26-078823-index.html | 0001104659-26-078823 |
| Document: 0001104659-26-078823.txt | 0001104659-26-078823 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 4, 2026 12w ago | 8-K | $20.10 $23.06 | ▲ +14.73% | ▲ +15.96% | $18.38 (−8.56%) |
Jul 1, 2026 16w ago | Insider Cluster | $19.52 $20.69 | ▲ +5.99% | ▲ +8.18% | $18.38 (−5.84%) |
Jun 30, 2026 16w ago | 8-K | $19.52 $20.69 | ▼ −5.99% | ▼ −8.18% | $18.38 (+5.84%) |
Jun 30, 2026 16w ago | 424B5 | $19.52 $20.69 | ▼ −5.99% | ▼ −8.18% | $18.38 (+5.84%) |
Jun 29, 2026 17w ago | Press Release | $18.39 $19.54 | ▼ −6.25% | ▼ −7.28% | $18.38 (+0.05%) |
Jun 29, 2026 17w ago | 424B5 | $18.39 $19.54 | ▼ −6.25% | ▼ −7.28% | $18.38 (+0.05%) |
Jun 29, 2026 17w ago | 8-K | $18.39 $19.54 | ▲ +6.25% | ▲ +7.28% | $18.38 (−0.05%) |
May 5, 2026 25w ago | 8-K | $9.71 $9.51 | ▼ −2.06% | ▼ −7.01% | $18.38 (+89.29%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers